This Metric Says You Are Smart to Buy Progenics Pharmaceuticals, Inc. (PGNX) – Cerus Corporation (CERS), XOMA Corp (XOMA)

Page 1 of 2

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) investors should pay attention to an increase in support from the world’s most elite money managers recently.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

In the eyes of most shareholders, hedge funds are assumed to be underperforming, outdated financial tools of yesteryear. While there are more than 8000 funds trading at the moment, we choose to focus on the upper echelon of this club, around 450 funds. It is estimated that this group has its hands on most of the smart money’s total capital, and by keeping an eye on their best investments, we have identified a few investment strategies that have historically beaten the S&P 500 index. Our small-cap hedge fund strategy beat the S&P 500 index by 18 percentage points per year for a decade in our back tests, and since we’ve began to sharing our picks with our subscribers at the end of August 2012, we have outclassed the S&P 500 index by 24 percentage points in 7 months (check out a sample of our picks).

Just as key, bullish insider trading activity is a second way to break down the financial markets. Just as you’d expect, there are plenty of reasons for a corporate insider to cut shares of his or her company, but only one, very obvious reason why they would buy. Several academic studies have demonstrated the useful potential of this strategy if shareholders understand what to do (learn more here).

Now, let’s take a gander at the key action surrounding Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

What does the smart money think about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)?

In preparation for this year, a total of 9 of the hedge funds we track held long positions in this stock, a change of 29% from one quarter earlier. With hedge funds’ capital changing hands, there exists a select group of notable hedge fund managers who were boosting their stakes substantially.

When looking at the hedgies we track, Broadfin Capital, managed by Kevin Kotler, holds the biggest position in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Broadfin Capital has a $11 million position in the stock, comprising 2.7% of its 13F portfolio. Sitting at the No. 2 spot is Tudor Investment Corp, managed by Paul Tudor Jones, which held a $7 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Remaining peers that hold long positions include James E. Flynn’s Deerfield Management, Julian Baker and Felix Baker’s Baker Bros. Advisors and Cliff Asness’s AQR Capital Management.

With a general bullishness amongst the heavyweights, some big names were breaking ground themselves. Broadfin Capital, managed by Kevin Kotler, assembled the largest position in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Broadfin Capital had 11 million invested in the company at the end of the quarter. James E. Flynn’s Deerfield Management also initiated a $4 million position during the quarter. The other funds with brand new PGNX positions are Julian Baker and Felix Baker’s Baker Bros. Advisors and Ben Levine, Andrew Manuel and Stefan Renold’s LMR Partners.

How have insiders been trading Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)?

Insider buying is at its handiest when the company in focus has experienced transactions within the past half-year. Over the last half-year time period, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has seen 1 unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s also take a look at hedge fund and insider activity in other stocks similar to Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). These stocks are XOMA Corp (NASDAQ:XOMA), Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), Curis, Inc. (NASDAQ:CRIS), Cerus Corporation (NASDAQ:CERS), and Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS). This group of stocks are in the biotechnology industry and their market caps match PGNX’s market cap.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!